Rasna Therapeutics (RASP) 10-K/A 9 Jun 22 2021 FY Annual report (amended) Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2021	May 31, 2022	Mar. 31, 2021
Document Information Line Items
Entity Registrant Name	RASNA THERAPEUTICS, INC.
Document Type	10-K/A
Current Fiscal Year End Date	--09-30
Entity Common Stock, Shares Outstanding		179,979,361
Entity Public Float			$ 2,632,000
Amendment Flag	true
Amendment Description	We are filing this Amendment No. 1 to our Form
 10-K for the fiscal year ended September 30, 2021, filed on March 1, 2022 (the “Original Filing”), to amend and restate our
 balance sheet as of September 30, 2021, and our statements of operations, shareholders’ equity, and cash flows for the year ended
 September 30, 2021. This Amendment to the Original Filing corrects a gain on extinguishment of debt that was incorrectly accounted for.
 As a result, the gain on extinguishment has been reversed.For the convenience of the reader, this Amendment
 sets forth our Original Filing in its entirety, as amended by the changes related to the restatement. This Amendment does not reflect
 events occurring after the filing of our Original Filing, or modify or update those disclosures, except as applicable in our financial
 statement footnote subsequent event disclosures. The following sections of our Original Filing have been amended:● Part I - Item 1A. Risk Factors.● Part II - Item 6 – Selected
 Financial Data;● Part II - Item 7 - Management’s
 Discussion and Analysis or Plan of Operation; and● Part II - Item 8 - Financial
 Statements.This Amendment has been signed as of a current
 date and all certifications of our Chief Executive Officer and Chief Financial Officer are given as of a current date. Accordingly, this
 Amendment should be read in conjunction with our filings made with the Securities and Exchange Commission subsequent to the filing of
 the Original Filing, including any amendments to those filings.
Entity Central Index Key	0001582249
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	333-191083
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	39-2080103
Entity Address, Address Line One	420 Lexington Ave
Entity Address, Address Line Two	Suite 2525
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10170
City Area Code	(646)
Local Phone Number	396-4087
Entity Interactive Data Current	Yes
Auditor Name	Mazars USA LLP
Auditor Location	Fort Washington, PA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Current assets:
Cash	$ 10,848	$ 14,241
Prepayments and other receivables	33,729	17,641
Related party receivable		748
Total current assets	44,577	32,630
Property and equipment, net		314
Total assets	44,577	32,944
Current liabilities:
Accounts payable and accrued expenses	1,516,001	1,635,788
Related party payables	561,446	550,000
Loan payable - related party	80,640	74,880
Derivative liabilities	38,018
Convertible notes payable - related party	230,287	89,768
Convertible notes payable	371,997	357,196
Total Current liabilities	2,798,389	2,707,632
Commitments and contingencies (Note 12)
Shareholders’ deficit
Common stock, $0.001 par value, 200,000,000 shares authorized; 68,908,003 issued and outstanding at both 2021 and 2020	68,909	68,909
Additional paid-in capital	20,711,758	19,914,884
Accumulated deficit	(23,534,479)	(22,658,481)
Total shareholders’ deficit	(2,753,812)	(2,674,688)
Total liabilities and shareholders’ deficit	$ 44,577	$ 32,944

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2021	Sep. 30, 2020
Statement of Financial Position [Abstract]
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	68,908,003	68,908,003
Common stock, shares outstanding	68,908,003	68,908,003

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue
Cost of revenue
Gross profit
Operating expenses:
General and administrative	247,814	556,504
Research and development
Impairment of intangible assets		2,149,369
Impairment of goodwill		2,722,985
Total operating expenses	247,814	5,428,858
Loss from operations	(247,814)	(5,428,858)
Other income/(expense):
Expenses in connection with modification and extinguishment of convertible promissory notes	(123,718)
Interest expense	(515,907)	(41,438)
Gain on sale of asset		120,000
Gain on troubled debt restructuring	11,773
Foreign currency transaction gain/(loss)	(332)	590
Other (expense)/income, net	(628,184)	79,152
Loss before provision for income taxes	(875,998)	(5,349,706)
Income tax benefit		(3,034)
Net loss	$ (875,998)	$ (5,346,672)
Basic and diluted loss per share attributable to common shareholders (in Dollars per share)	$ (0.01)	$ (0.08)
Basic weighted average common shares outstanding (in Shares)	68,908,003	68,908,003

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders’ Equity/(Deficit) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance at Sep. 30, 2019	$ 68,909	$ 19,780,252	$ (17,311,809)	$ 2,537,352
Beginning Balance (in Shares) at Sep. 30, 2019	68,908,003
Share based compensation		134,632		134,632
Net loss			(5,346,672)	(5,346,672)
Ending Balance at Sep. 30, 2020	$ 68,909	19,914,884	(22,658,481)	(2,674,688)
Ending Balance (in Shares) at Sep. 30, 2020	68,908,003
Share based compensation		42,673		42,673
Net loss			(875,998)	(875,998)
Fees relating to debt issuance		123,718		123,718
Beneficial conversion feature related to convertible notes		630,483		630,483
Ending Balance at Sep. 30, 2021	$ 68,909	$ 20,711,758	$ (23,534,479)	$ (2,753,812)
Ending Balance (in Shares) at Sep. 30, 2021	68,908,003

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (875,998)	$ (5,346,672)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	42,673	134,632
Fees related to convertible notes	123,718
Depreciation	314	1,635
Deferred income tax benefit		(3,034)
Non-cash interest expense	5,760	38,558
Write off of related party receivable		2,880
Impairment of goodwill		2,722,985
Impairment of intangible assets		2,149,369
Gain on troubled debt restructuring	(11,773)
Accretion of debt discount	545,594
Changes in operating assets and liabilities:
Prepayments and other receivables	(16,088)	(10,463)
Related party receivable	748	12,975
Accounts payable and accrued expenses	(119,787)	45,196
Related party payables	11,446	612
Net cash used in operating activities	(293,393)	(251,327)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes	290,000	143,500
Proceeds from issuance of loan payable – related party		72,000
Net cash provided by financing activities	290,000	215,500
Net (decrease) in cash	(3,393)	(35,827)
Cash at beginning of year	14,241	50,068
Cash at end of year	10,848	14,241
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Derivative liabilities in connection with debt extinguishments	38,018
Costs in connection with extinguishments of promissory notes	123,718
Beneficial conversion feature related to issuance of convertible notes	$ 630,483

Restatement of Prior Financial

Restatement of Prior Financial Information	12 Months Ended
	Sep. 30, 2021
Condensed Financial Information Disclosure [Abstract]
RESTATEMENT OF PRIOR FINANCIAL INFORMATION	1. RESTATEMENT OF PRIOR FINANCIAL INFORMATION On February 3, 2021, all outstanding convertible notes were modified with amended expiration and conversion terms. The Company incorrectly recognized a gain on the extinguishment of debt relating to these amended notes of $90,916, made up of the interest accrued on the notes to the date of expiration. This interest forms part of the fair value of the notes at extinguishment date. The Company has evaluated the financial statement impact in the previously filed reporting period effected and concluded that the changes are quantitatively material to its previously filed financial statements. The amounts previously recorded in the year ended September 30, 2021 have been adjusted to reduce equity and increase liabilities for the incorrectly recognized gain on extinguishment. The effect of the correction of this error on the balance sheet as of September 30, 2021 and the statement of operations and statement of cash flows for the twelve month period ended September 30, 2021 is as follows: Consolidated Balance Sheet September 30, Adjustments September 30, Current assets: Cash $ 10,848 $ — $ 10,848 Prepayments and other receivables 33,729 — 33,729 Related party receivable — — — Total current assets 44,577 — 44,577 — Property and equipment, net — — — Total assets $ 44,577 $ — $ 44,577 LIABILITIES AND SHAREHOLDERS’ DEFICIT Liabilities: Current liabilities: Accounts payable and accrued expenses $ 1,516,001 $ — $ 1,516,001 Related party payables 561,446 — 561,446 Loan payable - related party 80,640 — 80,640 Derivative liabilities 38,018 — 38,018 Convertible notes payable - related party 221,571 8,716 230,287 Convertible notes payable 289,797 82,200 371,997 Total Current liabilities 2,707,473 90,916 2,798,389 Commitments and contingencies (Note 11) — — — Shareholders’ deficit Common stock, $0.001 par value, 200,000,000 shares authorized; 68,908,003 issued and outstanding at both 2021 and 2020 68,909 — 68,909 Additional paid-in capital 20,711,758 — 20,711,758 Accumulated deficit (23,443,563 ) (90,916 ) (23,534,479 ) Total shareholders’ deficit (2,662,896 ) (90,916 ) (2,753,812 ) Total liabilities and shareholders’ deficit $ 44,577 $ — $ 44,577 Consolidated Statement of Operations September 30, Adjustments September 30, 2021 Revenue $ — $ — $ — Cost of revenue — — — Gross profit Operating expenses: General and administrative 247,814 247,814 Impairment of goodwill Total operating expenses 247,814 247,814 Loss from operations (247,814 ) (247,814 ) Other income/(expense): Expenses in connection with modification and extinguishment of convertible promissory notes (123,718 ) (123,718 ) Interest expense (515,907 ) (515,907 ) Gain on extinguishment of debt 90,916 (90,916 ) — Gain on troubled debt restructuring 11,773 11,773 Foreign currency transaction gain/(loss) (332 ) (332 ) Other (expense)/income, net (537,268 ) (90,916 ) (628,184 ) Loss before provision for income taxes (785,082 ) (90,916 ) (875,998 ) Income tax benefit - - - Net loss (785,082 ) (90,916 ) (875,998 ) Basic and diluted loss per share attributable to common shareholders (0.01 ) (0.01 Basic weighted avverage common shares outstanding 68,908,003 68,908,003 Consolidated Statement of Cash Flows September 30, Adjustments September 30, CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ (785,082 ) $ (90,916 ) $ (875,998 ) Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation 42,673 — 42,673 Fees related to convertible notes 123,718 — 123,718 Depreciation 314 314 Non-cash interest expense 5,760 — 5,760 Gain on troubled debt restructuring (11,773 ) (11,773 ) Gain on debt extinguishment (90,916 ) 90,916 — Accretion of debt discount 545,594 — 545,594 Changes in operating assets and liabilities: — Prepayments and other receivables (16,088 ) — (16,088 ) Related party receivable 748 — 748 Accounts payable and accrued expenses (119,787 ) — (119,787 Related party payables 11,446 — 11,446 Net cash used in operating activities (293,393 ) — (293,393 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of convertible notes 290,000 — 290,000 Net cash provided by financing activities 290,000 — 290,000 Net (decrease) in cash (3,393 ) — (3,393 ) Cash at beginning of year 14,241 — 14,241 Cash at end of year $ 10,848 $ — $ 10,848

General Information

General Information	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
GENERAL INFORMATION	2. GENERAL INFORMATION Rasna Therapeutics, Inc. ( “Rasna Inc.” or the “Company”), is a biotechnology company incorporated in the State of Delaware on March 28, 2016. The Company is engaged in modulating the molecular targets NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. These consolidated financial statements are presented in United States dollars (“USD”) which is also the functional currency of the in which the Company operates.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been applied consistently to all the periods presented unless otherwise stated. Basis of Presentation These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) including all pronouncements of the U.S. Securities and Exchange Commission applicable to annual financial statements. Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, Rasna Research Inc, and Rasna Rasna Research Inc’s subsidiary, Arna Therapeutics Limited. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements. Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to the carrying amount of intangible assets, the fair values of stock based awards, the modification and extinguishment of debt, derivatives and valuations associated with derivatives, income taxes and contingent liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates and such differences could be material to the Company’s consolidated financial position and results of operations. Fair Value of Financial Instruments Fair value is defined under FASB ASC Topic 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for an asset or liability in an orderly transaction between participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The levels are as follows: ● Level 1 - Quoted prices in active markets for identical assets or liabilities ● Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data for substantially the full term of the assets or liabilities ● Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities. The following is a listing of the Company’s liabilities required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of September 30, 2021: Level 1 Level 2 Level 3 Total Derivative Liability $ — $ — $ 38,018 $ 38,018 Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. Risks and Uncertainties The Company intends to operate in an industry that is subject to rapid change. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks associated with an early stage company, including the potential risk of business failure. In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic, which continues to spread throughout the United States and the World. There is considerable uncertainty around the expected duration of this pandemic. The COVID-19 pandemic and the public health responses to contain it have resulted in global recessionary conditions. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on the Company’s ability to access capital. Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s ability to raise capital, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Research and development Expenditures for research and development are charged to operations in the year in which they are incurred with the exception of expenditures incurred in respect of the development of major new products where the outcome of those projects is assessed as being reasonably certain in regards to viability and technical feasibility. Such expenditures are capitalized and amortized straight line over the estimated period of sale for each product, commencing in the year that sales of the product are first made. To date, the Company has not capitalized any such expenditures other than certain IPR&D & intellectual property (“IP”) recorded in connection with certain acquisition or equity transactions. Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Management considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings experience by jurisdiction, expectations of future taxable income, and the carryforward periods available for tax reporting purposes, as well as other relevant factors. A valuation allowance may be established to reduce deferred tax assets to the amount that management believes is more likely than not to be realized. Due to inherent complexities arising from the nature of the business, future changes in income tax law and variances between actual and anticipated operating results, management makes certain judgments and estimates. Therefore, actual income taxes could materially vary from these estimates. Changes in tax rates and tax laws are accounted for in the period of enactment. The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not to be sustained upon an examination, based on the technical merits of the position. The Company records a liability for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company’s tax return. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. To the extent interest and penalties are not assessed with respect to uncertain tax positions, amounts accrued will be reduced and reflected as a reduction of the overall income tax provision. The Company incurred no liability and, therefore, did not need to record interest and penalties during the years ended September 30, 2021 and 2020. Reclassification Certain amounts in prior periods related to the classification of operating expenses have been reclassified to conform to current period presentation. Foreign Currency Items included in the financial statements are measured using their functional currency, which is the currency of the primary economic environment in which the company operates. The accompanying financial statements are presented in United States Dollar (“USD”), which is the Company’s functional and presentational currency. Foreign currency transactions are translated using the rate of exchange applicable at the date of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-translation at the year-end of monetary assets and liabilities denominated in foreign currencies are recognized in the statements of operations. Net Loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per share includes potentially dilutive securities such as outstanding options, warrants and convertible loan notes, using the if-converted method in the determination of dilutive shares outstanding during each reporting period. The following table sets forth potential common shares issuable upon the exercise of outstanding options, the exercise of warrants and the conversion of notes and associated fees, all of which have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: September 30, 2021 2020 Stock options 3,648,675 3,210,050 Warrants 1,926,501 1,926,501 Convertible notes & associated fees 82,487,678 1,562,319 Total shares issuable upon exercise or conversion 88,062,854 6,698,870 The following is the computation of net loss per share for the following periods: For the For the 2021 2020 Net loss $ (875,998 ) $ (5,346,672 ) Weighted average number of shares 68,908,003 68,908,003 Net loss per share (basic and diluted) $ (0.01 ) $ (0.08 ) Equity-Based Payments The Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 “Compensation-Stock Compensation” requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award. The Company accounts for shares of common stock, stock options and warrants issued to employees based on the fair value of the stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received. The Company accounts for stock-based compensation awards issued to non-employees under ASC No. 718-10, Compensation – Stock Compensation – Overall, Convertible Notes Debt Discount The Company issued certain convertible notes that have certain embedded derivatives and/or required bifurcation. In connection with these features, the Company has recorded a discount to the debt that will be accreted to the face value of the note under the effective interest method over the term of the note. Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company does not intend to early adopt and continues to evaluate the impact of the provisions of ASU 2020-06 on its consolidated financial statements. In December 2019, the FASB issued ASU 2019 -12, Income Taxes - Simplifying the Accounting for Income Taxes (“ASU 2019-12”). Among other items, the amendments in ASU 2019-12 simplify the accounting treatment of tax law changes and year-to-date losses in interim periods. An entity generally recognizes the effects of a change in tax law in the period of enactment; however, there is an exception for tax laws with delayed effective dates. Under current guidance, an entity may not adjust its annual effective tax rate for a tax law change until the period in which the law is effective. This exception was removed under ASU 2019-12, thereby providing that all effects of a tax law change are recognized in the period of enactment, including adjustment of the estimated annual effective tax rate. Regarding year-to-date losses in interim periods, an entity is required to estimate its annual effective tax rate for the full fiscal year at the end of each interim period and use that rate to calculate its income taxes on a year-to-date basis. However, current guidance provides an exception that when a loss in an interim period exceeds the anticipated loss for the year, the income tax benefit is limited to the amount that would be recognized if the year-to-date loss were the anticipated loss for the full year. ASU 2019-12 removes this exception and provides that, in this situation, an entity would compute its income tax benefit at each interim period based on its estimated annual effective tax rate. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the effect that this update will have on its financial statements and related disclosures. The Company has determined that all other recently issued accounting pronouncements will not have a material impact on its consolidated financial position, results of operations and cash flows, or do not apply to its operations.

Liquidity and Going Concern

Liquidity and Going Concern	12 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY AND GOING CONCERN	4 . The Company is subject to a number of risks similar to those of other pre-commercial stage companies, including its dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with research, development, testing, and obtaining related regulatory approvals of its pipeline products, suppliers and collaborators, successful protection of intellectual property, competition with larger, better-capitalized companies, successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including obtaining adequate financing to fulfill its development activities and generating a level of revenues adequate to support the Company’s cost structure. The Company has experienced net losses and significant cash outflows from cash used in operating activities over the past two years, and as of September 30, 2021, had an accumulated deficit of $23,443,563, a net loss for the year ended September 30, 2021 of $875,998 and net cash used in operating activities of $293,393. The Company expects to continue to incur net losses and have significant cash outflows for at least the next 12 months and will require significant additional cash resources to launch new development phases of existing products in its pipeline. In the event that the Company is unable to secure the necessary additional cash resources needed, the Company may slow current development phases or halt new development phases in order to mitigate the effects of the costs of development. These conditions, among others, raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date these financial statements are issued. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support the Company’s cost structure.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES The following table summarizes the Company’s accounts payable and accrued expenses as of the following years : September 30, 2021 2020 Accounts payable $ 900,045 $ 952,151 Accrued expenses 615,956 683,637 $ 1,516,001 $ 1,635,788 Accounts payable is predominantly made up of unpaid invoices relating to research and development, accounting and professional fees. Included within the accrued expenses balance of $615,956 at September 30, 2021 is approximately $27,000 of accounting and professional fees, $208,000 of research and development fees, $309,000 for directors fees, and $72,000 for consultancy fees. Included within the accrued expenses balance of $683,637 at September 30, 2020 is approximately $110,000 of accrued legal, accounting and professional fees, $208,000 of research and development fees, $284,000 for directors fees, and $82,000 for consultancy fees.

Warrants

Warrants	12 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
WARRANTS	6. WARRANTS The Company had issued warrants to placement agents in lieu of fees for consultancy services and placement agent fees. Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, “Derivatives and Hedging - Contracts in an Entity’s Own Equity”, the Company determined that all the warrants issued are classified as equity in additional paid in-capital. The following table summarizes warrant activity for the years ended September 30, 2021 and 2020: Number of Weighted Average Exercise Weighted Average remaining Contractual Life (years) Aggregate Outstanding balance at October 1, 2019 1,926,501 0.43 6.86 $ — Granted — — — — Forfeited — — — — Outstanding balance at September 30, 2020 1,926,501 0.43 5.86 $ — Warrants exercisable at September 30, 2020 1,926,501 0.43 5.86 $ — Granted — — — — Forfeited — — — — Outstanding balance at September 30, 2021 1,926,501 0.43 4.86 $ — Warrants exercisable at September 30, 2021 1,926,501 0.43 4.86 $ —

Convertible Notes

Convertible Notes	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
CONVERTIBLE NOTES	7. CONVERTIBLE NOTES The table below summarizes outstanding convertible notes as of September 30, 2021 and 2020 : Balance of non-related notes payable, net as of September 30, 2019 264,907 Issuance of debt 57,500 Accrued Interest 34,789 Balance of non-related notes payable, net as of September 30, 2020 357,196 Issuance of debt 100,000 Beneficial conversion feature related to convertible notes issued (370,413 ) Derivative liability (22,088 ) Gain on troubled debt restructuring (11,773 ) Accretion of debt discount 319,075 Balance of non-related notes payable, net as of September 30, 2021 $ 371,997 Balance of related party notes payable, net as of September 30, 2019 - Issuance of debt 86,000 82203Accrued Interest 3,768 Balance of related party notes payable, net as of September 30, 2020 89,768 Issuance of debt 190,000 Beneficial conversion feature related to convertible notes issued (260,070 ) Derivative liability (15,930 ) Gain on troubled debt restructuring - Accretion of debt discount 226,519 Balance of related party notes payable, net as of September 30, 2021 $ 230,287 On October 21 2020, the Company entered into a seventh 12% Convertible Promissory Note with the Holder with a maturity date of October 21, 2021. The Holder provided the Company with $40,000 in cash. The Note provides the Holder with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price equal to the lower of (i) $0.05 per share or (ii) the price of the next equity financing, subject to adjustments noted within the Agreement. The number of shares issuable upon a conversion shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of the Note to be converted by (y) the Conversion Price. The Note requires the Company to reserve and keep available out of its authorized and unissued shares of common stock the amount of shares that would be issued upon conversion of the Note, which includes the outstanding principal amount of the Note and interest accrued and to be accrued through the date of maturity. On February 3, 2021, all outstanding notes were modified with amended expiry and conversion terms. The amended terms are as follows: 1. Conversion The amended Notes provide the Holders with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price equal to the lower of (i) $0.01 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement. 2. Expiry of the notes was amended to December 31, 2021. The Company determined that the modification of the debt instruments added a substantive conversion option at the date of the modification or exchange. Prior to the Note Amendments, the lowest conversion price of any of the Notes was $0.05 and ranged up to $0.65 (out of the money for all). At the date of the modification the conversion option price was repriced to $0.01, resulting in the conversion option for all notes being in the money on the day of the modification. On the day of the modification the fair value of the underlying stock was $0.05. As such, the modification added a substantive conversion option as of the conversion date and the amendment would be considered substantial. The notes were deemed to be extinguished and require extinguishment accounting. Under extinguishment accounting, the debt was remeasured and recorded at fair value. There was no difference between the carrying value of the debt, prior to the extinguishment, and the new fair value of the debt.t. The Company noted short term nature of the note and the fact that the stock was thinly traded with any trading activity resulting in a disproportionate effect on the stock price. Therefore, a Black Scholes valuation was deemed to be inappropriate in this case. The fair value of the amended notes was calculated as the principal plus interest. The fair value of the Notes on the extinguishment date was $509,416,which represented the principal plus interest at extinguishment date.. On January 14, 2021, the Company entered into a 12% Convertible Promissory Note with Panetta Partners Ltd. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $60,000 in cash. The Company promised to pay the principal amount, together with guaranteed interest at the annual rate of 12%, with principal and accrued interest on the Note due and payable on December 31, 2021 (unless converted under terms and provisions as set forth within the Agreement). The Note provides the Holder with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price equal to the lower of (i) $0.01 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement. The number of shares issuable upon a conversion shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of the Note to be converted by (y) the Conversion Price. The Note requires the Company to reserve and keep available out of its authorized and unissued shares of common stock the amount of shares that would be issued upon conversion of the Note, which includes the outstanding principal amount of the Note and interest accrued and to be accrued through the date of maturity. On February 10, 2021, the Company entered into another 12% Convertible Promissory Note with Panetta Partners Ltd. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $90,000 in cash. All other terms were the same as the note before. On May 25, 2021, the Company entered into a 1% Convertible Promissory Note with Laura Fonda. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $100,000 in cash. All other terms were the same as the note before. Embedded Derivative Liability Under the promissory note agreement, the interest rate will reset upon the event of a default and an additional penalty of 6% will be accrued. The Company analyzed the conversion features of the note agreement for derivative accounting consideration under ASC 815, Derivatives and Hedging, and determined the interest rate resets met the definition of a derivative. It also noted that the Contingent Interest Rate feature required bifurcation from the host note contract and was to be accounted for at fair value. In accordance with ASC 815-15, the Company bifurcated the Contingent Interest Rate feature of the note and recorded a derivative liability. The embedded derivatives for the notes are carried on the Company’s balance sheet at fair value. The Company noted due to the short-term nature of the note in addition to the relatively small incremental increase in the interest rate in the event of default (6%) the maximum overall impact would be approximately $38,018 (calculated as the increase in interest rate multiplied by the principal balance). In addition, the Company assessed all Events of Default and concluded that they are generally within the Company’s control and have a very low probability of occurrence. The notes carry an embedded derivative liability of $38,018 which will be amortized over the life of the note. Management will continue to assess the valuation of the embedded derivative at each reporting period and will record any changes in value through other income and expenses. Beneficial Conversion Feature The conversion features for all notes issued are in the money as of the issuance date and accordingly a beneficial conversion feature was recorded upon issuance. As the intrinsic value of the Beneficial Conversion Feature exceeds the face value, the recorded Beneficial Conversion Feature will be limited to the gross proceeds less any debt discounts. As at September 30, 2021 this amounted to $630,483. This Beneficial Conversion Feature will be amortized on a straight line basis over the term of the note. Troubled Debt Restructuring On September 30, 2021, the interest rate for a Note was reduced to 1%. The company evaluated the reduction under ASC 470 and concluded that there were indicators of financial difficulty at this date and a concession had been granted. Therefore the amendment should be accounted for under the troubled debt restructuring model. When a borrower has a troubled debt restructuring (“TDR”) in which the terms of its debt are modified, it should analyze the future undiscounted cash flows to determine the appropriate accounting treatment. The recognition and measurement guidance for a TDR depends on whether the future undiscounted cash flows specified by the new terms are greater or less than the carrying value of the debt. The Company determined that the future undiscounted cash flows under the new terms were less than the adjusted net carrying value of the original debt, therefore a gain of $11,773 was recorded for the difference on the statement of operations,

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	8. STOCK-BASED COMPENSATION 2016 EQUITY INCENTIVE PLAN On July 19, 2016, the Company adopted its 2016 Equity Incentive Plan (the “Equity Incentive Plan”). The Equity Incentive Plan was established to attract, motivate, retain and reward selected employees and other eligible persons. For the Equity Incentive Plan, employees, officers, directors and consultants who provide services to the Company or one of the Company’s subsidiaries may be selected to receive awards. A total of 9,750,000 shares of the Company’s common stock was authorized for issuance with respect to awards granted under the Equity Incentive Plan. Stock-based compensation expense is the estimated fair value of options granted amortized on a straight-line basis over the requisite service period for the entire portion of the award less an estimate for anticipated forfeitures. The Company uses the “simplified” method to estimate the expected term of the options because the Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. No options were granted during the years ended September 30, 2021 and 2020. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company’s stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of the Company’s stock options. The following table summarizes stock option activity for the years ended September 30, 2021 and September 30, 2020 Number of Weighted Weighted Aggregate Outstanding balance at October 1, 2019 4,073,675 0.59 6.37 $ — Granted — — — — Exercised — — — — Forfeited and Expired (425,000 ) (0.61 ) — — Outstanding balance at September 30, 2020 3,648,675 0.59 5.28 $ — Options exercisable at September 30, 2020 3,210,050 0.54 5.11 — Granted — — — — Exercised — — — — Forfeited and Expired — — — — Outstanding balance at September 30, 2021 3,648,675 0.59 4.28 $ — Options exercisable at September 30, 2021 3,648,675 0.59 4.28 $ — There were no options exercised during the years ended September 30, 2021 and September 30, 2020. As of September 30, 2021, there was no unrecognized compensation cost related to stock options. The charges related to share-based compensation to directors, officers and employees are included within the general and administrative expense category in the statement of operations. For the years ended September 30, 2021 and September 30, 2020, the charges were $42,673 and $134,632 respectively.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	9. INCOME TAXES The components of loss before income taxes consisted of the following: Year Ended Year Ended 2021 2020 US $ (875,998 ) $ (5,349,706 ) Foreign — — Total $ (875,998 ) $ (5,349,706 ) As of September 30, 2020, the Company is expected to have net operating loss carryforwards of approximately $7.7 million for federal tax purposes, which will expire in 2037. The utilization of these NOL’s may be subject to limitations based on past and future changes in ownership of the Company pursuant to Internal Revenue Code section 382. The Company has determined that ownership changes may have occurred for Internal Revenue Code section 382 purposes and therefore, the ability of the Company to utilize its NOLs may be limited. Income tax expenses attributable to income for continuing operations consists of: Year Ended Year Ended 2021 2020 Federal: Current — — Deferred $ (208,837 ) $ (169,925 ) Foreign: Current — — Deferred — — State and local: Current — — Deferred (78,662 ) (58,097 ) Change in valuation allowance 287,499 224,988 Income tax (benefit)/expense $ - $ (3,034 ) Deferred income taxes reflect the net tax effects of temporary differences between the carrying value of the asset and liabilities for financial reporting purposes and amounts used for income tax purposes. The temporary differences that gave rise to the deferred tax assets and liabilities are as follows: September 30, 2021 2020 Deferred tax assets: Accrued Compensation $ 89,385 $ 81,861 Stock Compensation 441,240 454,507 Net operating losses 2,453,820 2,215,640 R&D Credit carryforward 268,715 208,715 Fixed assets 136 523 Total gross deferred tax asset 3,253,296 2,961,246 Less: valuation allowance (3,297,288 ) (3,009,789 ) Net deferred tax asset (43,992 ) (48,543 ) Deferred tax liabilities: Intangible assets 43,992 48,543 Fixed assets — — Total Deferred tax liabilities 43,992 48,543 Net Deferred Income Tax $ — $ — At September 30, 2021 the Company had net operating loss carryforwards of approximately $8.5M for federal tax purposes. In assessing the realizability of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, net operating loss carryback potential, and tax planning strategies in making these assessments. Based upon the above criteria, the Company believes that it is more likely than not that the full amount of the remaining net deferred tax assets will not be realized. Accordingly, the Company has recorded a full valuation allowance of approximately $3.0 million against the deferred tax asset that is not expected to be realized. The Company recognizes interest accrued to unrecognized tax benefits and penalties as income tax expense. The Company accrued no penalties or interest during the years ended September 30, 2021 and September 30, 2020. A reconciliation of the statutory Federal Income tax rate and effective tax rate of the provision for income taxes is as follows: Year ended Year ended 2021 2020 Federal statutory rate 21.00 % 21.00 % Permanent items (0.01 )% (18.21 )% State taxes 7.09 % 0.86 % Increase in valuation allowance (32.82 )% (4.21 )% Impact of the change to Federal Statutory Tax - 1.12 % R&D Credit 6.85 % - Other (2.11 )% (0.50 )% Effective income tax rate 0.00 % 0.06 % The Company files tax returns as prescribed by the tax laws of the jurisdictions in which they operate. In the normal course of business, the Company is subject to examination by federal and foreign jurisdictions where applicable based on the statute of limitations that apply in each jurisdiction. As of September 30, 2021, open years related to the federal jurisdiction are fiscal years ending 2020, 2019, 2018, 2017 and 2016. The Company has no open tax audits for the returns that were filed, with any tax authority as of September 30, 2021. Accordingly, there were no material uncertain tax positions in any of the jurisdictions that the Company operated in.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	10. RELATED PARTY TRANSACTIONS During the normal course of its business, the Company enters into various transactions with entities that are both businesses and individuals. The following is a summary of the related party transactions during the years ended September 30, 2021 and 2020. Eurema Consulting Eurema Consulting S.r.l. is a significant shareholder of the Company. During the years ended September 30, 2021 and 2020, Eurema Consulting did not supply the Company with consulting services. As of September 30, 2021, and September 30, 2020, the balance due to Eurema Consulting S.r.l. was $200,000 for past consultancy services. Gabriele Cerrone Gabriele Cerrone is the majority shareholder of Panetta Partners, one of the Company’s principal shareholders. As of September 30, 2021, and September 30, 2020, the balance due to Gabriele Cerrone was $175,000 for past consultancy services. In March 2020, the Company entered into a 12% Convertible Promissory Note with Gabriele Cerrone for $20,000 with an extended maturity date of December 31, 2021. In February 2021, Gabriele Cerrone assigned the Note to Panetta Partners Ltd. Roberto Pellicciari and TES Pharma Roberto Pellicciari is the majority shareholder of TES Pharma Srl, one of the Company’s principal shareholders. During the years ended September 30, 2021 and 2020, Roberto Pellicciari did not supply the Company with consulting services. As of September 30, 2021, and September 30, 2020, the balance due to Roberto Pellicciari was $175,000 for past consultancy services. At both September 30, 2021 and September 30, 2020, TES Pharma was owed $75,000. Tiziana Life Sciences (“Tiziana”) The Company is party to a Shared Services Agreement with Tiziana, whereby the Company is charged for shared services and rent. Tiziana had previously agreed to waive all charges for shared services from October 2018 onwards, until further notice since the amounts due for such services are de minimis. Notice was given and recharges from October 1, 2020 were resumed. Keeren Shah the Company’s Finance Director is also Finance Director of Tiziana, and the Company’s directors, Willy Simon and John Brancaccio are also non-executive directors of Tiziana. As of September 30, 2021, $11,446 was due to Tiziana under services charged under the shared services agreement. This is recorded as a related party payable in the accompanying consolidated balance sheets. As of September 30, 2020, the Company made payments on behalf of Tiziana of $748, which are recorded as a related party receivable in the accompanying consolidated balance sheets. In March, 2020, Tiziana extended a loan facility to Rasna of $65,000. The loan is repayable within 18 months and is incurring an interest charge of 8% per annum. In April 2020, the loan facility was extended by a further $7,000, so the loan facility totals $72,000. As of September 30, 2021, the amounts due to Tiziana under this loan facility were $80,640. The amount due to Tiziana under this agreement as of September 30, 2020 was $74,880. Panetta Partners Panetta Partners Limited, a shareholder of Rasna, is a company in which Gabriele Cerrone is a major shareholder and also serves as a director. The Company has entered into numerous 12% Convertible Promissory Notes with Panetta Partners for a total of $256,000. The amount due for these notes as at September 30, 2021, with respect to the principal and accrued interest is $276,303. As at September 30, 2020 $68,501 was due with respect to notes issued. Apart from the Convertible Promissory Notes, there is no interest charged on the balances with related parties,. There are no defined repayment terms and such amounts can be called for payment at any time.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES Consultancy Agreements On October 1, 2020 the Company entered into a consultancy agreement with Keeren Shah in which she agreed to serve as Finance Director for a fee of $15,000 per year. During the year to September 30, 2021, the Company incurred approximately $15,000 of consultancy expenses related to this agreement. Shared Services Agreement The Company has entered into a shared services agreement with Tiziana Life Sciences. Under the terms of this agreement, the Company will be charged for shared administrative services including payroll and rent for the London premises, on a monthly basis based on allocated costs incurred. This agreement is effective from January 1, 2017. As at September 30, 2021, $11,446 is due to Tiziana Life Sciences.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS The Company has evaluated subsequent events that occurred after the balance sheet date up to the date that the consolidated financial statements were issued. Other than as disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements. During November 2021, Panetta Partners Ltd advanced $85,000 to the Company. This advance was converted into promissory notes, the terms of which are the same as those of all the outstanding promissory notes, The expiration of the notes is December 31, 2023. On December 31, 2021, the terms of all other outstanding promissory notes were extended to December 31, 2023. In February 2022, Panetta Partners Ltd advanced $30,000 to the Company. This advance was converted into promissory notes, at an interest rate of 16% with a conversion price of $0.005. In March 2022, Panetta Partners Ltd advanced an additional $45,000 to the Company. This advance was converted into promissory notes, at an interest rate of 16% with a conversion price of $0.005. In March 2022, the Company agreed to return back to TES Pharma S.R.L and Eurema Consulting S.R.L all intellectual property rights and assignments relating to NPM1. In exchange for this, TES Pharma S.R.L and Eurema Consulting S.R.L agreed to waive any payments due to them and their affiliates by Rasna. On May 13, 2022, the Company received notice from all noteholders that all notes were to be converted into stock. The Company issued 111,071,358 of common stock on May 13, 2022 in respect of these conversions.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) including all pronouncements of the U.S. Securities and Exchange Commission applicable to annual financial statements.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, Rasna Research Inc, and Rasna Rasna Research Inc’s subsidiary, Arna Therapeutics Limited. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to the carrying amount of intangible assets, the fair values of stock based awards, the modification and extinguishment of debt, derivatives and valuations associated with derivatives, income taxes and contingent liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates and such differences could be material to the Company’s consolidated financial position and results of operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined under FASB ASC Topic 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for an asset or liability in an orderly transaction between participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The levels are as follows: ● Level 1 - Quoted prices in active markets for identical assets or liabilities ● Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data for substantially the full term of the assets or liabilities ● Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities. The following is a listing of the Company’s liabilities required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of September 30, 2021: Level 1 Level 2 Level 3 Total Derivative Liability $ — $ — $ 38,018 $ 38,018
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less to be cash equivalents.
Risks and Uncertainties	Risks and Uncertainties The Company intends to operate in an industry that is subject to rapid change. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks associated with an early stage company, including the potential risk of business failure. In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic, which continues to spread throughout the United States and the World. There is considerable uncertainty around the expected duration of this pandemic. The COVID-19 pandemic and the public health responses to contain it have resulted in global recessionary conditions. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on the Company’s ability to access capital. Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s ability to raise capital, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Research and development	Research and development Expenditures for research and development are charged to operations in the year in which they are incurred with the exception of expenditures incurred in respect of the development of major new products where the outcome of those projects is assessed as being reasonably certain in regards to viability and technical feasibility. Such expenditures are capitalized and amortized straight line over the estimated period of sale for each product, commencing in the year that sales of the product are first made. To date, the Company has not capitalized any such expenditures other than certain IPR&D & intellectual property (“IP”) recorded in connection with certain acquisition or equity transactions.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Management considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings experience by jurisdiction, expectations of future taxable income, and the carryforward periods available for tax reporting purposes, as well as other relevant factors. A valuation allowance may be established to reduce deferred tax assets to the amount that management believes is more likely than not to be realized. Due to inherent complexities arising from the nature of the business, future changes in income tax law and variances between actual and anticipated operating results, management makes certain judgments and estimates. Therefore, actual income taxes could materially vary from these estimates. Changes in tax rates and tax laws are accounted for in the period of enactment. The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not to be sustained upon an examination, based on the technical merits of the position. The Company records a liability for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company’s tax return. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. To the extent interest and penalties are not assessed with respect to uncertain tax positions, amounts accrued will be reduced and reflected as a reduction of the overall income tax provision. The Company incurred no liability and, therefore, did not need to record interest and penalties during the years ended September 30, 2021 and 2020.
Reclassification	Reclassification Certain amounts in prior periods related to the classification of operating expenses have been reclassified to conform to current period presentation.
Foreign Currency	Foreign Currency Items included in the financial statements are measured using their functional currency, which is the currency of the primary economic environment in which the company operates. The accompanying financial statements are presented in United States Dollar (“USD”), which is the Company’s functional and presentational currency. Foreign currency transactions are translated using the rate of exchange applicable at the date of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-translation at the year-end of monetary assets and liabilities denominated in foreign currencies are recognized in the statements of operations.
Net Loss per Share	Net Loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per share includes potentially dilutive securities such as outstanding options, warrants and convertible loan notes, using the if-converted method in the determination of dilutive shares outstanding during each reporting period. The following table sets forth potential common shares issuable upon the exercise of outstanding options, the exercise of warrants and the conversion of notes and associated fees, all of which have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: September 30, 2021 2020 Stock options 3,648,675 3,210,050 Warrants 1,926,501 1,926,501 Convertible notes & associated fees 82,487,678 1,562,319 Total shares issuable upon exercise or conversion 88,062,854 6,698,870 The following is the computation of net loss per share for the following periods: For the For the 2021 2020 Net loss $ (875,998 ) $ (5,346,672 ) Weighted average number of shares 68,908,003 68,908,003 Net loss per share (basic and diluted) $ (0.01 ) $ (0.08 )
Equity-Based Payments	Equity-Based Payments The Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 “Compensation-Stock Compensation” requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the estimated fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award. The Company accounts for shares of common stock, stock options and warrants issued to employees based on the fair value of the stock, stock option or warrant, if that value is more reliably measurable than the fair value of the consideration or services received. The Company accounts for stock-based compensation awards issued to non-employees under ASC No. 718-10, Compensation – Stock Compensation – Overall,
Convertible Notes Payable	Convertible Notes Debt Discount The Company issued certain convertible notes that have certain embedded derivatives and/or required bifurcation. In connection with these features, the Company has recorded a discount to the debt that will be accreted to the face value of the note under the effective interest method over the term of the note.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company does not intend to early adopt and continues to evaluate the impact of the provisions of ASU 2020-06 on its consolidated financial statements. In December 2019, the FASB issued ASU 2019 -12, Income Taxes - Simplifying the Accounting for Income Taxes (“ASU 2019-12”). Among other items, the amendments in ASU 2019-12 simplify the accounting treatment of tax law changes and year-to-date losses in interim periods. An entity generally recognizes the effects of a change in tax law in the period of enactment; however, there is an exception for tax laws with delayed effective dates. Under current guidance, an entity may not adjust its annual effective tax rate for a tax law change until the period in which the law is effective. This exception was removed under ASU 2019-12, thereby providing that all effects of a tax law change are recognized in the period of enactment, including adjustment of the estimated annual effective tax rate. Regarding year-to-date losses in interim periods, an entity is required to estimate its annual effective tax rate for the full fiscal year at the end of each interim period and use that rate to calculate its income taxes on a year-to-date basis. However, current guidance provides an exception that when a loss in an interim period exceeds the anticipated loss for the year, the income tax benefit is limited to the amount that would be recognized if the year-to-date loss were the anticipated loss for the full year. ASU 2019-12 removes this exception and provides that, in this situation, an entity would compute its income tax benefit at each interim period based on its estimated annual effective tax rate. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the effect that this update will have on its financial statements and related disclosures. The Company has determined that all other recently issued accounting pronouncements will not have a material impact on its consolidated financial position, results of operations and cash flows, or do not apply to its operations.

Restatement of Prior Financia_2

Restatement of Prior Financial Information (Tables)	12 Months Ended
	Sep. 30, 2021
Condensed Financial Information Disclosure [Abstract]
Schedule of consolidated balance sheet	September 30, Adjustments September 30, Current assets: Cash $ 10,848 $ — $ 10,848 Prepayments and other receivables 33,729 — 33,729 Related party receivable — — — Total current assets 44,577 — 44,577 — Property and equipment, net — — — Total assets $ 44,577 $ — $ 44,577 LIABILITIES AND SHAREHOLDERS’ DEFICIT Liabilities: Current liabilities: Accounts payable and accrued expenses $ 1,516,001 $ — $ 1,516,001 Related party payables 561,446 — 561,446 Loan payable - related party 80,640 — 80,640 Derivative liabilities 38,018 — 38,018 Convertible notes payable - related party 221,571 8,716 230,287 Convertible notes payable 289,797 82,200 371,997 Total Current liabilities 2,707,473 90,916 2,798,389 Commitments and contingencies (Note 11) — — — Shareholders’ deficit Common stock, $0.001 par value, 200,000,000 shares authorized; 68,908,003 issued and outstanding at both 2021 and 2020 68,909 — 68,909 Additional paid-in capital 20,711,758 — 20,711,758 Accumulated deficit (23,443,563 ) (90,916 ) (23,534,479 ) Total shareholders’ deficit (2,662,896 ) (90,916 ) (2,753,812 ) Total liabilities and shareholders’ deficit $ 44,577 $ — $ 44,577
Schedule of consolidated statement of operations	September 30, Adjustments September 30, 2021 Revenue $ — $ — $ — Cost of revenue — — — Gross profit Operating expenses: General and administrative 247,814 247,814 Impairment of goodwill Total operating expenses 247,814 247,814 Loss from operations (247,814 ) (247,814 ) Other income/(expense): Expenses in connection with modification and extinguishment of convertible promissory notes (123,718 ) (123,718 ) Interest expense (515,907 ) (515,907 ) Gain on extinguishment of debt 90,916 (90,916 ) — Gain on troubled debt restructuring 11,773 11,773 Foreign currency transaction gain/(loss) (332 ) (332 ) Other (expense)/income, net (537,268 ) (90,916 ) (628,184 ) Loss before provision for income taxes (785,082 ) (90,916 ) (875,998 ) Income tax benefit - - - Net loss (785,082 ) (90,916 ) (875,998 ) Basic and diluted loss per share attributable to common shareholders (0.01 ) (0.01 Basic weighted avverage common shares outstanding 68,908,003 68,908,003
Schedule of consolidated statement of cash flows	September 30, Adjustments September 30, CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ (785,082 ) $ (90,916 ) $ (875,998 ) Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation 42,673 — 42,673 Fees related to convertible notes 123,718 — 123,718 Depreciation 314 314 Non-cash interest expense 5,760 — 5,760 Gain on troubled debt restructuring (11,773 ) (11,773 ) Gain on debt extinguishment (90,916 ) 90,916 — Accretion of debt discount 545,594 — 545,594 Changes in operating assets and liabilities: — Prepayments and other receivables (16,088 ) — (16,088 ) Related party receivable 748 — 748 Accounts payable and accrued expenses (119,787 ) — (119,787 Related party payables 11,446 — 11,446 Net cash used in operating activities (293,393 ) — (293,393 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of convertible notes 290,000 — 290,000 Net cash provided by financing activities 290,000 — 290,000 Net (decrease) in cash (3,393 ) — (3,393 ) Cash at beginning of year 14,241 — 14,241 Cash at end of year $ 10,848 $ — $ 10,848

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of company’s liabilities	Level 1 Level 2 Level 3 Total Derivative Liability $ — $ — $ 38,018 $ 38,018
Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants	September 30, 2021 2020 Stock options 3,648,675 3,210,050 Warrants 1,926,501 1,926,501 Convertible notes & associated fees 82,487,678 1,562,319 Total shares issuable upon exercise or conversion 88,062,854 6,698,870
Schedule of net loss per share	For the For the 2021 2020 Net loss $ (875,998 ) $ (5,346,672 ) Weighted average number of shares 68,908,003 68,908,003 Net loss per share (basic and diluted) $ (0.01 ) $ (0.08 )

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued expenses	September 30, 2021 2020 Accounts payable $ 900,045 $ 952,151 Accrued expenses 615,956 683,637 $ 1,516,001 $ 1,635,788

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of warrant activity	Number of Weighted Average Exercise Weighted Average remaining Contractual Life (years) Aggregate Outstanding balance at October 1, 2019 1,926,501 0.43 6.86 $ — Granted — — — — Forfeited — — — — Outstanding balance at September 30, 2020 1,926,501 0.43 5.86 $ — Warrants exercisable at September 30, 2020 1,926,501 0.43 5.86 $ — Granted — — — — Forfeited — — — — Outstanding balance at September 30, 2021 1,926,501 0.43 4.86 $ — Warrants exercisable at September 30, 2021 1,926,501 0.43 4.86 $ —

Convertible Notes (Tables)

Convertible Notes (Tables)	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of convertible notes	Balance of non-related notes payable, net as of September 30, 2019 264,907 Issuance of debt 57,500 Accrued Interest 34,789 Balance of non-related notes payable, net as of September 30, 2020 357,196 Issuance of debt 100,000 Beneficial conversion feature related to convertible notes issued (370,413 ) Derivative liability (22,088 ) Gain on troubled debt restructuring (11,773 ) Accretion of debt discount 319,075 Balance of non-related notes payable, net as of September 30, 2021 $ 371,997 Balance of related party notes payable, net as of September 30, 2019 - Issuance of debt 86,000 82203Accrued Interest 3,768 Balance of related party notes payable, net as of September 30, 2020 89,768 Issuance of debt 190,000 Beneficial conversion feature related to convertible notes issued (260,070 ) Derivative liability (15,930 ) Gain on troubled debt restructuring - Accretion of debt discount 226,519 Balance of related party notes payable, net as of September 30, 2021 $ 230,287

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Schedule of stock option activity	Number of Weighted Weighted Aggregate Outstanding balance at October 1, 2019 4,073,675 0.59 6.37 $ — Granted — — — — Exercised — — — — Forfeited and Expired (425,000 ) (0.61 ) — — Outstanding balance at September 30, 2020 3,648,675 0.59 5.28 $ — Options exercisable at September 30, 2020 3,210,050 0.54 5.11 — Granted — — — — Exercised — — — — Forfeited and Expired — — — — Outstanding balance at September 30, 2021 3,648,675 0.59 4.28 $ — Options exercisable at September 30, 2021 3,648,675 0.59 4.28 $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Schedule of components of loss before income taxes	Year Ended Year Ended 2021 2020 US $ (875,998 ) $ (5,349,706 ) Foreign — — Total $ (875,998 ) $ (5,349,706 )
Schedule of income tax expenses	Year Ended Year Ended 2021 2020 Federal: Current — — Deferred $ (208,837 ) $ (169,925 ) Foreign: Current — — Deferred — — State and local: Current — — Deferred (78,662 ) (58,097 ) Change in valuation allowance 287,499 224,988 Income tax (benefit)/expense $ - $ (3,034 )
Schedule of deferred income taxes	September 30, 2021 2020 Deferred tax assets: Accrued Compensation $ 89,385 $ 81,861 Stock Compensation 441,240 454,507 Net operating losses 2,453,820 2,215,640 R&D Credit carryforward 268,715 208,715 Fixed assets 136 523 Total gross deferred tax asset 3,253,296 2,961,246 Less: valuation allowance (3,297,288 ) (3,009,789 ) Net deferred tax asset (43,992 ) (48,543 ) Deferred tax liabilities: Intangible assets 43,992 48,543 Fixed assets — — Total Deferred tax liabilities 43,992 48,543 Net Deferred Income Tax $ — $ —
Schedule of federal Income tax rate and effective tax rate	Year ended Year ended 2021 2020 Federal statutory rate 21.00 % 21.00 % Permanent items (0.01 )% (18.21 )% State taxes 7.09 % 0.86 % Increase in valuation allowance (32.82 )% (4.21 )% Impact of the change to Federal Statutory Tax - 1.12 % R&D Credit 6.85 % - Other (2.11 )% (0.50 )% Effective income tax rate 0.00 % 0.06 %

Restatement of Prior Financia_3

Restatement of Prior Financial Information (Details)	Feb. 03, 2021USD ($)
Condensed Financial Information Disclosure [Abstract]
Gain on the extinguishment of debt	$ 90,916

Restatement of Prior Financia_4

Restatement of Prior Financial Information (Details) - Schedule of consolidated balance sheet	Sep. 30, 2021USD ($)
As Previously Reported [Member]
Current assets:
Cash	$ 10,848
Prepayments and other receivables	33,729
Related party receivable
Total current assets	44,577
Property and equipment, net
Total assets	44,577
Current liabilities:
Accounts payable and accrued expenses	1,516,001
Related party payables	561,446
Loan payable - related party	80,640
Derivative liabilities	38,018
Convertible notes payable - related party	221,571
Convertible notes payable	289,797
Total Current liabilities	2,707,473
Commitments and contingencies (Note 11)
Shareholders’ deficit
Common stock, $0.001 par value, 200,000,000 shares authorized; 68,908,003 issued and outstanding at both 2021 and 2020	68,909
Additional paid-in capital	20,711,758
Accumulated deficit	(23,443,563)
Total shareholders’ deficit	(2,662,896)
Total liabilities and shareholders’ deficit	44,577
Adjustments [Member]
Current assets:
Cash
Prepayments and other receivables
Related party receivable
Total current assets
Property and equipment, net
Total assets
Current liabilities:
Accounts payable and accrued expenses
Related party payables
Loan payable - related party
Derivative liabilities
Convertible notes payable - related party	8,716
Convertible notes payable	82,200
Total Current liabilities	90,916
Commitments and contingencies (Note 11)
Shareholders’ deficit
Common stock, $0.001 par value, 200,000,000 shares authorized; 68,908,003 issued and outstanding at both 2021 and 2020
Additional paid-in capital
Accumulated deficit	(90,916)
Total shareholders’ deficit	(90,916)
Total liabilities and shareholders’ deficit
As Restated [Member]
Current assets:
Cash	10,848
Prepayments and other receivables	33,729
Related party receivable
Total current assets	44,577
Property and equipment, net
Total assets	44,577
Current liabilities:
Accounts payable and accrued expenses	1,516,001
Related party payables	561,446
Loan payable - related party	80,640
Derivative liabilities	38,018
Convertible notes payable - related party	230,287
Convertible notes payable	371,997
Total Current liabilities	2,798,389
Commitments and contingencies (Note 11)
Shareholders’ deficit
Common stock, $0.001 par value, 200,000,000 shares authorized; 68,908,003 issued and outstanding at both 2021 and 2020	68,909
Additional paid-in capital	20,711,758
Accumulated deficit	(23,534,479)
Total shareholders’ deficit	(2,753,812)
Total liabilities and shareholders’ deficit	$ 44,577

Restatement of Prior Financia_5

Restatement of Prior Financial Information (Details) - Schedule of consolidated balance sheet (Parentheticals)	Sep. 30, 2021$ / sharesshares
As Previously Reported [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Common stock, par value (in Dollars per share) | $ / shares	$ 0.001
Common stock, shares authorized	200,000,000
Common stock shares issued	68,908,003
Common stock shares outstanding	68,908,003
Adjustments [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Common stock, par value (in Dollars per share) | $ / shares	$ 0.001
Common stock, shares authorized	200,000,000
Common stock shares issued	68,908,003
Common stock shares outstanding	68,908,003
As Restated [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Common stock, par value (in Dollars per share) | $ / shares	$ 0.001
Common stock, shares authorized	200,000,000
Common stock shares issued	68,908,003
Common stock shares outstanding	68,908,003

Restatement of Prior Financia_6

Restatement of Prior Financial Information (Details) - Schedule of consolidated statement of operations	12 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
As Previously Reported [Member]
Condensed Income Statements, Captions [Line Items]
Revenue
Cost of revenue
Operating expenses:
General and administrative	247,814
Total operating expenses	247,814
Loss from operations	(247,814)
Other income/(expense):
Expenses in connection with modification and extinguishment of convertible promissory notes	(123,718)
Interest expense	(515,907)
Gain on extinguishment of debt	90,916
Gain on troubled debt restructuring	11,773
Foreign currency transaction gain/(loss)	(332)
Other (expense)/income, net	(537,268)
Loss before provision for income taxes	(785,082)
Income tax benefit
Net loss	$ (785,082)
Basic and diluted loss per share attributable to common shareholders (in Dollars per share) | $ / shares	$ (0.01)
Basic weighted avverage common shares outstanding (in Shares) | shares	68,908,003
Adjustments [Member]
Condensed Income Statements, Captions [Line Items]
Revenue
Cost of revenue
Other income/(expense):
Gain on extinguishment of debt	(90,916)
Other (expense)/income, net	(90,916)
Loss before provision for income taxes	(90,916)
Income tax benefit
Net loss	(90,916)
As Restated [Member]
Condensed Income Statements, Captions [Line Items]
Revenue
Cost of revenue
Operating expenses:
General and administrative	247,814
Total operating expenses	247,814
Loss from operations	(247,814)
Other income/(expense):
Expenses in connection with modification and extinguishment of convertible promissory notes	(123,718)
Interest expense	(515,907)
Gain on extinguishment of debt
Gain on troubled debt restructuring	11,773
Foreign currency transaction gain/(loss)	(332)
Other (expense)/income, net	(628,184)
Loss before provision for income taxes	(875,998)
Income tax benefit
Net loss	$ (875,998)
Basic and diluted loss per share attributable to common shareholders (in Dollars per share) | $ / shares	$ 0.01
Basic weighted avverage common shares outstanding (in Shares) | shares	68,908,003

Restatement of Prior Financia_7

Restatement of Prior Financial Information (Details) - Schedule of consolidated statement of cash flows	12 Months Ended
	Sep. 30, 2021USD ($)
As Previously Reported [Member]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (785,082)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	42,673
Fees related to convertible notes	123,718
Depreciation	314
Non-cash interest expense	5,760
Gain on troubled debt restructuring	(11,773)
Gain on debt extinguishment	(90,916)
Accretion of debt discount	545,594
Changes in operating assets and liabilities:
Prepayments and other receivables	(16,088)
Related party receivable	748
Accounts payable and accrued expenses	(119,787)
Related party payables	11,446
Net cash used in operating activities	(293,393)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes	290,000
Net cash provided by financing activities	290,000
Net (decrease) in cash	(3,393)
Cash at beginning of year	14,241
Cash at end of year	10,848
Adjustments [Member]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	(90,916)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation
Fees related to convertible notes
Non-cash interest expense
Gain on debt extinguishment	90,916
Accretion of debt discount
Changes in operating assets and liabilities:
Prepayments and other receivables
Related party receivable
Accounts payable and accrued expenses
Related party payables
Net cash used in operating activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes
Net cash provided by financing activities
Net (decrease) in cash
Cash at beginning of year
Cash at end of year
As Restated [Member]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	(875,998)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	42,673
Fees related to convertible notes	123,718
Depreciation	314
Non-cash interest expense	5,760
Gain on troubled debt restructuring	(11,773)
Gain on debt extinguishment
Accretion of debt discount	545,594
Changes in operating assets and liabilities:
Prepayments and other receivables	(16,088)
Related party receivable	748
Accounts payable and accrued expenses	119,787
Related party payables	11,446
Net cash used in operating activities	(293,393)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes	290,000
Net cash provided by financing activities	290,000
Net (decrease) in cash	(3,393)
Cash at beginning of year	14,241
Cash at end of year	$ 10,848

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of company’s liabilities - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of company’s liabilities [Line Items]
Derivative Liability	$ 38,018
Level 1 [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of company’s liabilities [Line Items]
Derivative Liability
Level 2 [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of company’s liabilities [Line Items]
Derivative Liability
Level 3 [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of company’s liabilities [Line Items]
Derivative Liability	$ 38,018

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants - shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares issuable upon exercise or conversion	88,062,854	6,698,870
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares issuable upon exercise or conversion	1,926,501	1,926,501
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares issuable upon exercise or conversion	3,648,675	3,210,050
Convertible notes & associated fees [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares issuable upon exercise or conversion	82,487,678	1,562,319

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of net loss per share - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Schedule of net loss per share [Abstract]
Net loss	$ (875,998)	$ (5,346,672)
Weighted average number of shares	68,908,003	68,908,003
Net loss per share (basic and diluted)	$ (0.01)	$ (0.08)

Liquidity and Going Concern (De

Liquidity and Going Concern (Details) - Liquidity and Going Concern [Member]	12 Months Ended
	Sep. 30, 2021USD ($)
Liquidity and Going Concern (Details) [Line Items]
Accumulated deficit	$ 23,443,563
Net loss	(875,998)
Net cash used in operating activities	$ (293,393)

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Payables and Accruals [Abstract]
Accrued expenses	$ 615,956	$ 683,637
Accounting and professional fees	27,000
Research and development fees	208,000	284,000
Directors fees	309,000
Consultancy fees	$ 72,000	82,000
Accrued legal		110,000
Accrued Professional Fees		$ 208,000

Accounts Payable and Accrued _4

Accounts Payable and Accrued Expenses (Details) - Schedule of accounts payable and accrued expenses - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Schedule of accounts payable and accrued expenses [Abstract]
Accounts payable	$ 900,045	$ 952,151
Accrued expenses	615,956	683,637
Total accounts payable and accrued expenses	$ 1,516,001	$ 1,635,788

Warrants (Details) - Schedule o

Warrants (Details) - Schedule of warrant activity - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Schedule of warrant activity [Abstract]
Number of Warrants, Outstanding opening balance (in Shares)	1,926,501	1,926,501
Weighted Average Exercise Price Per Option, Outstanding opening balance	$ 0.43	$ 0.43
Weighted Average remaining Contractual Life (years), Outstanding opening balance		6 years 10 months 9 days
Aggregate Intrinsic Value, Outstanding opening balance (in Dollars)
Number of Warrants, Granted (in Shares)
Weighted Average Exercise Price Per Option, Granted
Number of Warrants, Forfeited (in Shares)
Weighted Average Exercise Price Per Option, Forfeited
Number of Warrants, Outstanding ending balance (in Shares)	1,926,501	1,926,501
Weighted Average Exercise Price Per Option, Outstanding ending balance	$ 0.43	$ 0.43
Weighted Average remaining Contractual Life (years), Outstanding ending balance	4 years 10 months 9 days	5 years 10 months 9 days
Aggregate Intrinsic Value, Outstanding ending balance (in Dollars)
Number of Warrants, Warrants exercisable ending balance (in Dollars)	$ 1,926,501	$ 1,926,501
Weighted Average Exercise Price Per Option, Warrants exercisable ending balance	$ 0.43	$ 0.43
Weighted Average remaining Contractual Life (years), Warrants exercisable ending balance	4 years 10 months 9 days
Number of Warrants, Warrants exercisable opening balance (in Dollars)	$ 1,926,501
Weighted Average Exercise Price Per Option, Warrants exercisable opening balance	$ 0.43
Weighted Average remaining Contractual Life (years), Warrants exercisable opening balance	5 years 10 months 9 days

Convertible Notes (Details)

Convertible Notes (Details) - USD ($)	Feb. 10, 2021	Jan. 14, 2021	Oct. 21, 2020	Dec. 31, 2020	Sep. 30, 2021	May 25, 2021	Sep. 30, 2020
Convertible Notes (Details) [Line Items]
Convertible promissory note in percentage			12.00%
Cash				$ 40,000
Convertible note Per share (in Dollars per share)					$ 0.05
Conversion, description					The amended Notes provide the Holders with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price equal to the lower of (i) $0.01 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement.
Convertible notes description					The Company determined that the modification of the debt instruments added a substantive conversion option at the date of the modification or exchange. Prior to the Note Amendments, the lowest conversion price of any of the Notes was $0.05 and ranged up to $0.65 (out of the money for all). At the date of the modification the conversion option price was repriced to $0.01, resulting in the conversion option for all notes being in the money on the day of the modification. On the day of the modification the fair value of the underlying stock was $0.05. As such, the modification added a substantive conversion option as of the conversion date and the amendment would be considered substantial. The notes were deemed to be extinguished and require extinguishment accounting. Under extinguishment accounting, the debt was remeasured and recorded at fair value. There was no difference between the carrying value of the debt, prior to the extinguishment, and the new fair value of the debt.
Extinguishment gain					$ 509,416
Interest rate					1.00%
Cash						$ 100,000
Interest rate					6.00%
Interest rate in percentage					6.00%
Short-term Debt					$ 38,018
Derivative liability					38,018
Gross proceeds debt discount					630,483
Net carrying value					$ 11,773
Convertible Promissory Note [Member]
Convertible Notes (Details) [Line Items]
Interest rate	12.00%	12.00%				1.00%
Cash received from the Holder		$ 60,000
Convertible Promissory Note [Member]
Convertible Notes (Details) [Line Items]
Cash received from the Holder	$ 90,000
Price of equity financing		$ 1,000,000
Note Due On December 21, 2021 [Member] | Convertible Promissory Note [Member]
Convertible Notes (Details) [Line Items]
Interest rate		12.00%
Debt discount (in Dollars per share)		$ 0.01

Convertible Notes (Details) - S

Convertible Notes (Details) - Schedule of convertible notes - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Non-Related Party Notes Payable [Member]
Convertible Notes (Details) - Schedule of convertible notes [Line Items]
Balance			$ 264,907
Issuance of debt	$ 100,000	$ 57,500
Accrued Interest		34,789
Balance	371,997	357,196
Beneficial conversion feature related to convertible notes issued	(370,413)
Derivative liability	(22,088)
Gain on troubled debt restructuring	(11,773)
Accretion of debt discount	319,075
Related Party Notes Payable [Member]
Convertible Notes (Details) - Schedule of convertible notes [Line Items]
Balance
Issuance of debt	190,000	86,000
Accrued Interest		3,768
Balance	230,287	$ 89,768
Beneficial conversion feature related to convertible notes issued	(260,070)
Derivative liability	(15,930)
Gain on troubled debt restructuring
Accretion of debt discount	$ 226,519

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-Based Payment Arrangement [Abstract]
Common stock, shares authorized (in Shares)	9,750,000
General and administrative expense	$ 42,673	$ 134,632

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of stock option activity - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Schedule of stock option activity [Abstract]
Number of Options, Beginning balance	3,648,675	4,073,675
Weighted Average Exercise Price Per Option, Beginning balance	$ 0.59	$ 0.59
Weighted Average remaining Contractual Life (years), Beginning balance		6 years 4 months 13 days
Number of Options, Granted
Weighted Average Exercise Price Per Option, Granted
Aggregate Intrinsic Value, Granted
Number of Options, Exercised
Weighted Average Exercise Price Per Option, Exercised
Aggregate Intrinsic Value, Exercised
Number of Options, Forfeited and Expired		(425,000)
Weighted Average Exercise Price Per Option, Forfeited and Expired		$ (0.61)
Aggregate Intrinsic Value, Forfeited and Expired
Number of Options, Ending balance	3,648,675	3,648,675
Weighted Average Exercise Price Per Option, Ending balance	$ 0.59	$ 0.59
Weighted Average remaining Contractual Life (years), Ending balance	4 years 3 months 10 days	5 years 3 months 10 days
Aggregate Intrinsic Value, Ending balance
Number of Options, Options exercisable	3,648,675	3,210,050
Weighted Average Exercise Price Per Option, Options exercisable	$ 0.59	$ 0.54
Weighted Average remaining Contractual Life (years), Options exercisable	4 years 3 months 10 days	5 years 1 month 9 days
Aggregate Intrinsic Value, Options exercisable

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Federal tax purposes	$ 8.5	$ 7.7
Valuation allowance	$ 3

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of components of loss before income taxes - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Schedule of components of loss before income taxes [Abstract]
US	$ (875,998)	$ (5,349,706)
Foreign
Total	$ (875,998)	$ (5,349,706)

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of income tax expenses - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Federal:
Current
Deferred	(208,837)	(169,925)
Foreign:
Current
Deferred
State and local:
Current
Deferred	(78,662)	(58,097)
Change in valuation allowance	287,499	224,988
Income tax (benefit)/expense		$ (3,034)

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of deferred income taxes - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Deferred tax assets:
Accrued Compensation	$ 89,385	$ 81,861
Stock Compensation	441,240	454,507
Net operating losses	2,453,820	2,215,640
R&D Credit carryforward	268,715	208,715
Fixed assets	136	523
Total gross deferred tax asset	3,253,296	2,961,246
Less: valuation allowance	(3,297,288)	(3,009,789)
Net deferred tax asset	(43,992)	(48,543)
Deferred tax liabilities:
Intangible assets	43,992	48,543
Fixed assets
Total Deferred tax liabilities	43,992	48,543
Net Deferred Income Tax

Income Taxes (Details) - Sche_4

Income Taxes (Details) - Schedule of federal Income tax rate and effective tax rate	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Schedule of federal Income tax rate and effective tax rate [Abstract]
Federal statutory rate	21.00%	21.00%
Permanent items	(0.01%)	(18.21%)
State taxes	7.09%	0.86%
Increase in valuation allowance	(32.82%)	(4.21%)
Impact of the change to Federal Statutory Tax		1.12%
R&D Credit	6.85%
Other	(2.11%)	(0.50%)
Effective income tax rate	0.00%	0.06%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Apr. 30, 2020	Mar. 31, 2020
Related Party Transactions (Details) [Line Items]
Balance due to Eurema consulting services	$ 200,000	$ 200,000
Promissory note		748
Balance due to related party	561,446	550,000	$ 7,000
Company owed		75,000
Loan facility amount			$ 72,000
Accrued interest	$ 80,640	74,880
Related party transactions, description	As of September 30, 2021, and September 30, 2020, the balance due to Gabriele Cerrone was $175,000 for past consultancy services.
Gabriele Cerrone [Member]
Related Party Transactions (Details) [Line Items]
Interest charge, percentage				12.00%
Promissory note				$ 20,000
Maturity date	Dec. 31, 2021
Roberto Pellicciari and TES Pharma [Member]
Related Party Transactions (Details) [Line Items]
Balance due to related party	$ 175,000	175,000
Company owed	75,000
Tiziana Life Sciences PLC [Member]
Related Party Transactions (Details) [Line Items]
Interest charge, percentage				8.00%
Service charges	$ 11,446
Related party receivable		748
Principal and accrued interest amount				$ 65,000
Panetta Partners [Member]
Related Party Transactions (Details) [Line Items]
Interest charge, percentage	12.00%
Principal and accrued interest amount	$ 276,303
Total interest charge	$ 256,000
Notes issued		$ 68,501

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Oct. 01, 2020	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Finance director fee	$ 15,000
Consultancy expenses		$ 15,000
Shared services agreement		$ 11,446

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	1 Months Ended
	Mar. 31, 2022	Feb. 28, 2022	Nov. 30, 2021	May 13, 2022
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Advanced amount			$ 85,000
Forecast [Member]
Subsequent Events (Details) [Line Items]
Advanced amount	$ 45,000	$ 30,000
Interest rate	16.00%	16.00%
Conversion price (in Dollars per share)	$ 0.005	$ 0.005
Common stock, shares issued (in Shares)				111,071,358